← Back to search

ACADIA PHARMACEUTICALS INC.

ACAD · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.